---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-197971"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:33:15.130979+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma enters $150M ATM equity offering with TD Cowen as agent

## Summary
- Amended Sales Agreement replaces Cowen and Company with TD Cowen as sole sales agent.
- Company may issue and sell up to $150M in ordinary shares at market prices via ATM offering.
- No shares were sold under the prior December 2023 sales agreement.
- TD Cowen receives up to 3% commission on gross sales; company has no obligation to sell.
- Sales may be made through an affiliate of TD Cowen; agreement terminable at will by either party.

## SEC filing metadata
- accession: 0001193125-24-197971
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524197971/0001193125-24-197971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524197971/d823291d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-197971
- JSON: https://secwatch.observer/filing/0001193125-24-197971.json
- Plain text: https://secwatch.observer/filing/0001193125-24-197971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.